Citations

Clear

1011 citation(s) found for "Barry, WT".

Heart Failure With Preserved Ejection Fraction In Perspective
Shah, Amil M. , Borlaug, Barry A. , Borlaug, Barry A , Shah, Amil , Pfeffer, Marc Alan

Mayo Clinic

Circulation Research | May 23, 2019 | Volume: 124 | Issue: 11 | Pages: 1598-1617

10.1161/circresaha.119.313572 | PMID 31120821 Get It

Approximately half of the patients with signs and symptoms of heart failure have a left ventricular ejection fraction that is not markedly abnormal. Despite the historically initial surprise, heightened risks for heart failure specific major adverse events occur across the broad range of ejection fraction, including normal. The recognition of the magnitude of the problem of heart failure with preserved ejection fraction in the past 20 years has spurred an explosion of clinical investigation and growing intensity of informative outcome trials. This article addresses the historic development of this component of the heart failure syndrome, including the epidemiology, pathophysiology, and existing and planned therapeutic studies. Looking forward, more specific phenotyping and even genotyping of subpopulations should lead to improvements in outcomes from future trials.
Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions
Reddy, Yogesh N.V. , Borlaug, Barry A. , O’Connor, Christopher M. , Nishimura, Rick , Borlaug, Barry A , Gersh, Bernard J.

Mayo Clinic

European Heart Journal | May 10, 2019 | Volume: 41 | Issue: 18 | Pages: 1764-1774

10.1093/eurheartj/ehz364 | PMID 31199474 Get It

Abstract Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions.
Faculty Opinions recommendation of Nitrosative stress drives heart failure with preserved ejection fraction.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 1, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735518661.793559275 Get It

Young and strong: A randomized study to improve care for young women with breast cancer.
Ruddy, Kathryn J. , Barry, William T., Ligibel, Jennifer A. , Sprunck‐Harrild, Kim , Rosenberg, Shoshana M. , Baker, Emily, Hoverman, J. Russell , Partridge, Ann H. , Greaney, Mary L. , Emmons, Karen M.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9588-9588

10.1200/jco.2015.33.15_suppl.9588 Get It

Faculty Opinions recommendation of Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 17, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735328399.793558687 Get It

Faculty Opinions recommendation of Diastolic ventricular interaction in heart failure with preserved ejection fraction.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 16, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735415166.793558686 Get It

Faculty Opinions recommendation of Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 16, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735328400.793558685 Get It

Right ventricular and pulmonary vascular function indices for risk stratification of patients with pulmonary regurgitation
Egbe, Alexander C. , Miranda, William R. , Pellikka, Patricia A. , Pislaru, Sorin V. , Borlaug, Barry A. , Kothapalli, Srikanth, Ananthaneni, Sindhura, Najam, Maria , Abdelsamid, Mohamed Farouk, Connolly, Heidi M. , Sandhyavenu, Harigopal , Farouk Abdelsamid, Mohamed, Sabbah, Michael S. , Pellikka, Patricia A , Borlaug, Barry A

Mayo Clinic

Congenital Heart Disease | April 8, 2019 | Volume: 14 | Issue: 4 | Pages: 657-664

10.1111/chd.12768 | PMID 30957982 Get It

Breaking tolerance with engineered class I antigen-presenting molecules
Parks, Christopher A. , Henning, Kalli R., Hansen, Michael J. , Keulen, Virginia P. Van , Reed, Brendan , Schrum, Adam G. , Gil, Diana , Kranz, David M. , Bordner, Andrew J., Barry, Michael A. , Pease, Larry R. , Pavelko, Kevin D. , Reed, Brendan K, Schrum, Adam G , Barry, Michael A , Stone, Jennifer D.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 1, 2019 | Volume: 116 | Issue: 8 | Pages: 3136-3145

10.1073/pnas.1807465116 | PMID 30728302 Get It

Significance Provision of sufficient activating signals can drive self-tolerant T cells to cross-react on self-peptide-MHC in a breakdown of tolerance. This approach has been applied in the development of heteroclitic peptide vaccines, which retain sufficient similarity to self to allow reactivation of effector cells on unaltered self-epitopes but require detailed knowledge about the behavior of individual altered self-peptide antigens. We designed altered-self MHC mutant antigen-presenting molecules to drive CTL capable of cross-reacting on self-peptide-MHC and demonstrate the breaking of self-tolerance to defined and undefined self-antigens. These findings bear particular importance in the field of cancer immunotherapy in which breaking tolerance to weakly antigenic cancer-associated antigens is fundamental to vaccination strategies.
Left Atrial Strain and Compliance in the Diagnostic Evaluation of Heart Failure with Preserved Ejection Fraction
Reddy, Yogesh N.V. , Obokata, Masaru , Egbe, Alexander C. , Pislaru, Sorin V. , Lin, Grace , Carter, Rickey E. , Borlaug, Barry A. , Pislaru, Sorin, Carter, Rickey, Sabbah, Michael S. , Nishimura, Rick , Borlaug, Barry A , Carter, Rickey E , Obokata, Masaru , Yang, Jeong Hoon

Mayo Clinic

European Journal of Heart Failure | March 28, 2019 | Volume: 21 | Issue: 7 | Pages: 891-900

10.1002/ejhf.1464 | PMID 30919562 Get It

Abstract Aims Left atrial (LA) function is impaired in heart failure with preserved ejection fraction (HFpEF) and predicts disease severity and risk of adverse outcome. We sought to evaluate whether LA strain could enhance diagnosis of HFpEF. Methods and results Consecutive patients with unexplained exertional dyspnoea and image quality suitable for measuring LA strain underwent invasive cardiopulmonary exercise testing to ascertain the presence of HFpEF or non-cardiac causes of dyspnoea (NCD). LA reservoir strain was measured in all patients, while LA conduit and booster strain were measured in patients with sinus rhythm. LA strain was measurable in 363 of 378 examinations (96.5%; HFpEF: 238, NCD: 125). LA reservoir strain (29 ± 16% vs. 40 ± 13%, P < 0.0001) and conduit strain (18 ± 10% vs. 22 ± 10%, P = 0.0001) were significantly impaired in HFpEF compared to NCD. Of all echocardiographic indices, LA reservoir strain best discriminated HFpEF from NCD [area under the curve (AUC) 0.719, P < 0.0001], outperforming E/e' (AUC difference +0.117, P < 0.0001), LA enlargement (+0.090, P = 0.001), tricuspid regurgitation velocity > 2.8 m/s (+0.082, P = 0.0085), left ventricular hypertrophy (+0.0159, P < 0.0001) and left ventricular global longitudinal strain (+0.0198, P < 0.0001). Indexing LA reservoir strain to estimated LA pressure (E/e') as a surrogate for LA compliance further improved diagnostic performance (AUC 0.772, P < 0.0001; +0.053 compared to LA reservoir strain alone, P = 0.003). Conclusion Left atrial reservoir strain may provide enhanced diagnostic accuracy beyond conventional echocardiographic measures to discriminate HFpEF from NCD. Further study is required to verify the diagnostic utility of LA strain.